Lanraplenib (GS-SYK)

Synonyms: GS-9876

Lanraplenib (GS-SYK)is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

Lanraplenib (GS-SYK) Chemical Structure

Lanraplenib (GS-SYK) Chemical Structure

CAS No. 1800046-95-0

Purity & Quality Control

Batch: S971501 DMSO]89 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 98.64%
98.64

Lanraplenib (GS-SYK) Related Products

Signaling Pathway

Biological Activity

Description Lanraplenib (GS-SYK)is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
Targets
GPVI receptor [2] Syk [1]
(Cell-free assay)
9.5 nM
In vitro
In vitro

GS-9876 inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50 values of 24–51 nM. Functionally, GS-9876 inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, GS-9876 inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively). Anti-CD3/anti-CD28 stimulated T cell proliferation is weakly inhibited (EC50=1291±398 nM), with selectivity >10-fold versus the inhibition of B cell proliferation. In human blood, GS-9876 blocks SYK phosphorylation, CD69 expression on B cells, and CD63 expression in basophils.[1] GS-9876 inhibits glycoprotein VI (GPVI)-induced phosphorylation of linker for activation of T cells and phospholipase Cγ2, platelet activation and aggregation in human whole blood, and platelet binding to collagen under arterial flow.[2]

Cell Research Cell lines Human blood platelets
Concentrations 0.01 μM to 100 μM
Incubation Time 15 min
Method

Blood is preincubated for 15 min with Lanraplenib (GS-9876) and activated with ADP (0.2 μM) or convulxin (30 ng/mL) for 2 min at room temperature. Samples are stained for CD61 and CD62P, fixed, and analyzed on a FACSCanto II flow cytometer. The percentages of CD62P+ platelets are quantified and the values are subjected to nonlinear regression analysis using Prism 6 to generate EC50 values.

In Vivo
In vivo

GS-9876 demonstrates a dose-dependent improvement in clinical score and histopathology parameters with once-daily dosing in short and long term rat models of collagen-induced arthritis (CIA). Significant efficacy can be achieved with GS-9876 doses that produces trough pSYK inhibition of <50%.[1] Ex vivo, GPVI-stimulated platelet aggregation is inhibited in GS-9876-treated monkeys without a concomitant increase in bleeding time (BT). Similarly, orally administered GS-9876 does not increase BT in humans.[2]

Animal Research Animal Models female cynomolgus monkeys
Dosages 5 mg/kg, 15 mg/kg, 45 mg/kg
Administration Oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05028751 Terminated
Acute Myeloid Leukemia|Relapsed Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
Kronos Bio
August 5 2022 Phase 1|Phase 2
NCT02959138 Completed
Inflammatory Disease
Gilead Sciences
November 21 2016 Phase 1

Chemical Information & Solubility

Molecular Weight 443.50 Formula

C23H25N9O

CAS No. 1800046-95-0 SDF --
Smiles NC1=CN=CC(=N1)C2=C[N]3C=CN=C3C(=N2)NC4=CC=C(C=C4)N5CCN(CC5)C6COC6
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 89 mg/mL ( (200.67 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lanraplenib (GS-SYK) | Lanraplenib (GS-SYK) supplier | purchase Lanraplenib (GS-SYK) | Lanraplenib (GS-SYK) cost | Lanraplenib (GS-SYK) manufacturer | order Lanraplenib (GS-SYK) | Lanraplenib (GS-SYK) distributor